ReviewCancer immunology, immunotherapy : CII2013
Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.
Review in Cancer immunology, immunotherapy : CII, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma.Cancer science · 2017Trial
- Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine.Cancer science · 2017Trial
- Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.Cancer science · 2017Trial
- A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.Cancer immunology, immunotherapy : CII · 2016Trial
- Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.Cancer science · 2015Trial
- Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.Cancer science · 2015Trial
- Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.Cancer immunology, immunotherapy : CII · 2015Trial
- Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.Journal of immunology research · 2015Trial
- Clinical significance of immune-related antigen CD58 in gliomas and analysis of its potential core related gene clusters.Heliyon · 2024Article
- Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer.Molecular oncology · 2023Article
- Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer.Life (Basel, Switzerland) · 2023Review
- Frequencies of an Immunogenic HER-2/International journal of molecular sciences · 2023Article
- The Cellular and Molecular Immunotherapy in Prostate Cancer.Vaccines · 2022Review
- Immune responses of patients without cancer recurrence after a cancer vaccine over a long term.Molecular and clinical oncology · 2022Article
- Potential association factors for developing effective peptide-based cancer vaccines.Frontiers in immunology · 2022Article
- Development of Cancer Immunotherapies.Cancer treatment and research · 2022Article
- Article
- Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer.Molecular and clinical oncology · 2021Article
- Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.Cancers · 2021Review
- Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since both tumor cells and host immune cell repertoires are diverse and heterogeneous, immune responses against tumor-associated antigens should differ substantially among individual cancer patients. Selection of suitable peptide vaccines for individual patients based on the preexisting host immunity before vaccination could induce potent anti-tumor responses that provide clinical benefit to cancer patients. We have developed a novel immunotherapeutic approach of personalized peptide vaccination (PPV) in which a maximum of four human leukocyte antigen (HLA) class IA-matched peptides are selected for vaccination among pooled peptides on the basis of both HLA class IA type and the preexisting host immunity before vaccination. In this review, we discuss our recent results of preclinical and clinical studies of PPV for various types of advanced cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.